Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity

July 17th 2025

David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.

A Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management

July 17th 2025

Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.

Dr Hamilton on Unmet Needs for Brain Metastases in HER2+ Metastatic Breast Cancer

July 17th 2025

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

Second-Generation BTK Inhibitors Set the Stage for Future Advances in CLL Management

July 17th 2025

Cyrus M. Khan, MD, discusses the role of second-generation BTK inhibitors and their implications for clinical practice in the CLL treatment paradigm.

Mirdametinib Represents Long-Awaited Approved Treatment Option for Adult NF1-Associated PNs

July 17th 2025

Justin T. Jordan, MD, MPH, FAAN, discusses the implications of the FDA approval of mirdametinib for adult NF1-associated plexiform neurofibromas.

Long-Term Follow-Up Data With IO/IO and IO/TKI Combinations Better Inform Clinical Decision-Making in Advanced ccRCC

July 16th 2025

Hans Hammers, MD, PhD, discusses the efficacy, safety, and clinical utilization of IO/IO and IO/TKI combinations in advanced clear-cell RCC.

Dr Wilky on the Role of Personalized Therapy in GIST

July 16th 2025

Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.

Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma

July 15th 2025

Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification

July 15th 2025

Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.

Dr Singhi on the Rationale for Evaluating Lurbinectedin Plus Atezolizumab in ES-SCLC

July 15th 2025

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Dr Qin on Ongoing Investigations of Radium-223 in mCRPC

July 15th 2025

Qian (Janie) Qin, MD, discusses efforts to elucidate the optimal use of radium 223 plus enzalutamide in metastatic castration-resistant prostate cancer.

Tambiciclib Plus Azacitidine and Venetoclax Elicits Robust Antitumor Activity in R/R AML

July 15th 2025

Tambiciclib plus azacitidine and venetoclax generated favorable ORR, OS, and safety outcomes in patients with relapsed/refractory acute myeloid leukemia.

Early Safety Data Show Tolerability of Apalutamide Plus Carotuximab in Metastatic CRPC

July 15th 2025

Apalutamide plus carotuximab has been demonstrated to be well tolerated in patients with metastatic castration-resistant prostate cancer

Dr Huppert on Evolving First-Line Treatment Standards for HER2+ Metastatic Breast Cancer

July 14th 2025

Laura Huppert, MD, discusses ways that the frontline use of T-DXd in HER2-positive metastatic breast cancer may affect later-line treatment decisions.

Dr Bekaii-Saab on the Expanding Targeted Therapy Paradigm for Biliary Tract Cancers

July 14th 2025

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’

July 13th 2025

Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.

Dr Kremyanskaya on the Mechanism of Action of Divesiran in Polycythemia Vera

July 11th 2025

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL

July 11th 2025

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.

Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer

July 11th 2025

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Dr Saad on the Efficacy and Safety of Radium-223 Plus Enzalutamide in mCRPC

July 11th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.